Whalesbook
FY26 Results: Profit Declines 60% Amid ₹33.25 Crore Reversal
Bajaj Healthcare Ltd announced its audited financial results for the fiscal year ended March 31, 2026. Revenue from operations grew to ₹611.03 crore, up from ₹542.60 crore in FY25. However, net profit saw a significant drop of over 60%, falling to ₹15.77 crore from ₹39.50 crore in the prior fiscal year. This sharp decline was primarily caused by a ₹33.25 crore income reversal due to regional instability affecting a key customer's commitment.
Key Announcements and Developments
The Board of Directors recommended a final dividend of ₹1.50 per equity share, subject to shareholder approval.
JCR & Co. LLP has been appointed as the new Internal Auditors for FY2026-27, with V.J. Talati & Co. continuing as Cost Auditors.
The proposed acquisition of Genrx Pharmaceuticals Private Limited carries a consideration of ₹10.85 crore and awaits National Company Law Tribunal (NCLT) approval.
Significance and Risks
The ₹33.25 crore income reversal overshadowed the company's revenue growth for FY26. Despite this, the proposed dividend suggests management confidence. A primary risk is exposure to external factors impacting customer commitments, while successful execution of the Genrx acquisition is crucial for future growth.
What Investors Are Watching
Shareholders will monitor the approval of the ₹1.50 final dividend.
Progress on the NCLT's decision for the Genrx Pharmaceuticals acquisition is critical.
Updates on management strategies to mitigate risks from customer-related instability will also be important.